Advances in recombinant DNA technology have resulted in the production of biologic products that can be applied to clinical medicine for diagnostic and therapeutic purposes. Over the past decade, the potential of gene therapy as a treatment modality for inherited and acquired disorders has emerged. This technology involves the insertion of normal genes into the somatic cells of patients to correct an inherited or acquired disorder through the synthesis of missing or defective gene products in vivo (Anderson 1984; Belmont and Caskey 1986) . A variety of approaches to human gene transfer are currently under experimental investigation (reviewed by Friedmann 1989) . A protocol to treat people who have adenosine deaminase deficiency has recently begun at the National Institutes of Health, but gene therapy is still Elizabeth G. Nabel is at the Division of Cardiology, Department of Internal Medicine; and Gary J. Nabel is at the Departments of Internal Medicine and Biochemistry, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, MI 48109-0688, USA.
in a formative stage and has not yet successfully treated human disease. Several gene transfer protocols, which use recombinant genes as markers to study disease, are also in progress.
Various mechanical, chemical, and viral methods have been employed to introduce recombinant genes into host cells of different organ systems. These include the bone marrow (Hock and Miller 1986; Lemischka et al. 1986 ), liver (Wilson et al. 1988a and b) , lymphocytes (Belldegrun et al. 1989) , central nervous system (Palella et al. i988) , and lung (Garver et al. 1987a and b) . This review focuses on attempts to target gene modification to cardiovascular disorders, particularly diseases of the vasculature. 
Gene Transfer Approaches
To successfully deliver DNA to host cells, a gene transfer system must meet several requirements, including (a) high efficiency of transmission: (b) stable replication of the foreign DNA, either as an integrated transgene or as an extrachromosomal element; (c) (Doethschman et al. 1987; Mansour et al. 1988) .
Gene augmentation is a more established technique for modifying the expression of mutant genes in defective cells by introducing foreign normal genetic sequences into the host genome and leaving the host genes unaltered. Using this technique, it is possible to restore genetic function by the introduction of functional genes into nonspecific sites in the host genome without removal of the nonfunctional, mutant gene. Although mutational events could arise from the integration of foreign sequences at ectopic sites in the genome, this complication has not yet arisen in practice. For this reason, gene augmentation has received considerable attention. that is, they can infect a variety of cell types from different species. Retroviruses produce efficient infection of the host cell, followed by integration of the foreign gene into the host cell. However, there are several important safety issues that must be addressed before viral vectors can be used on a routine clinical basis. Most important is the need to demonstrate that the retrovirus cannot replicate ad hoc in the host cell or form wild-type recombinants that could replicate in an unregulated manner. These potential complications can be minimized by altering the viral genome to render the virus replication defective.
Most retroviral vectors used in experimental studies are derived from amphotropic murine or avian retroviruses. A viral vector is constructed by first deleting the structural genes required for viral replication (gag, pol, and env genes) from the retroviral genome (Cepko et al. 1984) , but retaining a sequence required for viral packaging.
Foreign DNA is ligated into the deleted genome of the retrovirus. This retroviral vector is introduced into a packaging cell line into which the structural genes (which lack a packaging signal) have previously been transfected (Danos and Mulligan 1988) ( Figure 1 ). The structural genes, provided in trans in the packaging cell, allow the production of a virus particle containing the foreign DNA. The viral particle can infect a host cell, the foreign DNA is inserted into a random site in the host genome, and the host cell can express the foreign gene.
The simplest vectors contain a single gene. In this form, a single gene is ligated into the defective retroviral genome, and this gene is regulated by the long terminal repeat sequences in the native virus. Multiple gene vectors incorporate more than one (generally two) gene(s) into the viral backbone, each under regulation from separate promoters.
Often, a selectable marker (that is, drug resistance gene) is introduced along with the foreign gene so that relatively pure populations of cells expressing the foreign gene can be isolated.
Retroviruses and their vectors are thought to integrate almost entirely into random sites in the host cell genome. Random integration could potentially lead to insertional mutagenesis through the interruption of cellular genes or through the insertion of retroviral regulatory sequences that modulate the expression of cellular genes. In practice, this complication has not been reproducibly observed.
Another potential problem with the use of defective retroviral vectors is the appearance of wild-type virus in producer cells through the recombination between the transfected vector plasmid and endogenous retrovirus-like sequences. To reduce the possibilities for productive recombination, helper cell lines that express the gag, pol, and env genes have been produced from separate plasmids with independent selectable markers (Danos and Mulligan 1988). Rodgers 1988) and modulate smooth muscle cell growth and tone (Furchgott and Zawadzki 1980; Berk et al. 1986; Palmer et al. 1987) . One approach to the treatment of local vascular disease would be to express genes at specific sites in the circulation that might ameliorate the process in situ. Because endothelial cells are found at diseased sites, they represent potential carriers to convey therapeutic agents, which might include anticoagulant, vasodilatory, angiogenic, or growth inhibitor factors. Endothelial cell gene modification then could be a therapeutic approach to the treatment of some vascular disorders. Alternatively, the myocardial cell is also a potential target for gene transfer, in order to (Figure 3) . The genetically altered endo- Two to four weeks later, the arterial segments inoculated with the 8-galactosidase expressing endothelium were removed and examined.
Examination of the gross sections of artery segment after histochemical staining revealed areas of blue coloration, indicating P-galactosidase expression (Figure 2D) (Nabel et al. 1989) . Under light microscopy, 8-galactosidase staining was observed in endothelial cells in the intima layer ( Figure 2F ) (Nabel et al. 1989 (Dichek et al. 1989) .
Because endothelial cells line all blood vessels, they are an ideal target to direct gene products into the bloodstream to treat other systemic or inherited disorders.
For example, the factor-VIII gene could be introduced into a population of endothelial cells (in a microcirculation) and the factor-VIII protein produced by the modified endothelium could in turn correct a hemophilia disorder.
l Direct Gene Transfer into the Arterial Wall
The previous studies established the feasibility of genetically altering endothelial cells in vitro and implanting them in vivo. However, it would be difficult to use this technique clinically, since it might take several weeks to genetically prepare a patient's cells in vitro prior to in situ instillation. Rather, it would be advantageous to directly modify vascular cells in vivo, for example, during 
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01991, Elsevier Science Publishing Co., 1050-1738/91/$2.00 catheterization. We have performed further experiments to test the hypothesis that vascular cells could be directly transduced in vivo. Using the same porcine model described above, the l%galactosidase expressing retroviral vector was directly instilled into an iliofemoral artery segment (Nabel et al. 1990 ). These arterial segments were infected by the retrovirus in vivo and expressed the recombinant P-galactosidase gene for at least 5 months. We found that all three cell wall layers were infected including intima, media, and adventia. Further immunohistochemical studies demonstrated that endothelial and vascular smooth muscle cells were primarily infected. In addition to directly transferring genes into arterial 'cells with a retrovirus, our subsequent experiments have demonstrated that DNA can also be transfected into vascular cells by using liposomes. This latter technique offers several advantages over retroviruses, including safety and ease of preparation.
To ensure that infection of the arterial segments with a replication-defective retrovirus is safe, we examined all pigs for the presence of helper virus, reverse transcriptase activity, and P-galactosidase activity in liver, lung, kidney and spleen. We found no evidence for retrovirus or P-galactosidase activity in these organs for up to S months.
These studies demonstrate that direct gene transfer can be achieved in vivo by infection with a retroviral vector or transfection with liposomes and that the genetic modification is limited to the site of cell transduction.
Before these techniques can be applied to the treatment of human disease, several major concerns must be resolved. The level of expression of the foreign gene should be determined. The stability and longevity of gene expression must be understood. Promoters and enhancers that regulate gene expression need to be well characterized. Untoward cellular events resulting from overexpression of recombinant genes must be determined. Safety aspects need to be delineated and the risk to benefit ratio of introducing recombinant genes into host organisms must be defined. 
